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Abstract 
Background: The indirubin derivative 7‑bromoindirubin‑3′‑oxime (7BIO) has already shown anticancer properties 
by causing cell death in some tumour cell lines and may be a new therapeutic option for treatment‑resistant tumour 
cells. Since dedifferentiated and anaplastic thyroid carcinomas do not take up radioiodine and are insensitive to 
chemotherapeutic treatment and external radiation, direct cell death induction in these tumour cells may be a prom‑
ising approach. We thus investigated the effect of 7BIO on thyroid carcinoma cell lines of different histological origins 
and characterized the type of cell death induction by 7BIO.
Methods: Cell viability was measured with MTT assay. Cell death was analysed by caspase 3/7 activity, lactate dehy‑
drogenase liberation, caspase cleavage products, DNA fragmentation, cell cycle phase distribution and LC3B analysis.
Results: After 7BIO treatment, cell viability was reduced in all 14 thyroid carcinoma cell lines investigated. Treated 
cells showed DNA fragmentation, cell cycle arrest and lactate dehydrogenase liberation but no LC3B cleavage. 
Caspase activation following 7BIO treatment was found in five of six cell lines investigated. Interestingly, inhibition of 
caspases had no effect on viability of the cells after 7BIO incubation.
Conclusions: Our results indicate that 7BIO efficiently killed dedifferentiated thyroid carcinoma cells. It induced a 
non‑classical kind of cell death that was caspase‑independent and includes DNA fragmentation. 7BIO and related 
indirubin components thus may have value as a new therapeutic option for dedifferentiated thyroid cancer irrespec‑
tive of the exact target molecules and the kind of cell death they induce.
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Background
The bis-indole alkaloid indirubin is the active compound 
of a traditional Chinese herbal medicine used for treat-
ment of chronic myelocytic leukemia. Thus, indirubins 
are of interest as possible anti-tumour substances [1]. 
Indirubin and its analogues (referred to as indirubins) 
are naturally found in certain indigo-dye producing 
plants and sea shells [Review: 2], while various deriva-
tives have been synthesized to improve the effects on 
tumour cells. Among the bromo-substituted indiru-
bins, 7-bromoindirubin-3′-oxime (7BIO) showed activ-
ity against some tumour cell lines by inducing cell death 
[3–5]. While other indirubins were shown to inhibit 
cyclin-dependent kinases (CDKs), glycogen synthase 
kinase-3 (GSK-3), Janus activated kinases (JAK), SRC 
and subsequently STAT3 and AKT [6–11], 7BIO showed 
only marginal inhibitory effects towards these kinases 
but triggered a rapid cell death [3]. An inhibitory screen-
ing of 7BIO on 85 kinases was performed that revealed 
that only FLT3 was inhibited by 7BIO with an IC50 below 
1 µM [3]. Despite the fact that the exact molecular mech-
anism of action of 7BIO is not yet known, it may be valu-
able for inducing cell death in tumour cells.
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The imbalance between cell division and cell death 
pathways is one characteristic feature of cancer cells 
and contributes to the “hallmark of cancer cells” [12]. 
Decreased cell death in general is associated with hyper-
proliferative diseases like cancer and resistance to cell 
death contributes to uncontrolled tumour proliferation 
[13]. Cell death can be induced by different pathways 
that are regulated by different intracellular signalling cas-
cades, i.e., mainly apoptosis, necrosis, necroptosis, and 
autophagy [Review: 14]. According to the Nomencla-
ture Committee on Cell Death [15], apoptosis is a form 
of regulated cell death characterized by the activation 
of caspases, a family of cysteine proteases [16]. Caspase 
activation leads to a degradation of specific substrates, to 
a fragmentation of nuclear DNA, and, in turn, to char-
acteristic morphological changes of the affected cells [17, 
18]. Necrosis on the other hand is characterized by cell 
swelling and early plasma membrane permeabilisation 
followed by cell rupture and the release of cellular mate-
rial [Review: 19]. Biochemically, lysosomal hydroxylases 
are often released during necrosis and are involved in 
cell destruction [20]. Autophagy, as the third type of cell 
death mechanism, describes the process of self-digestion 
of cellular components by the cells [Review: 21]. During 
this regulated cellular process organelles and cell compo-
nents are degraded and recycled and thus, in addition to 
inducing death in single cells, it is also a survival mecha-
nism for the whole cell population in situations like star-
vation or cellular damage [22].
Thyroid carcinoma is the most common endocrine 
malignancy, accounting for nearly 95  % of malignant 
endocrine tumours [23]. Most thyroid carcinomas (95–
97  %) originate from follicular thyroid cells, whereas 
about 3–5  % of thyroid carcinomas are medullary sub-
types derived from C-cells [24]. About 90  % of the thy-
roid cancers of follicular cell origin are well differentiated 
papillary thyroid carcinoma (PTC; 70–80 %) or follicular 
thyroid carcinoma (FTC; 10–20  %). While differenti-
ated subtypes still take up radioiodine and have a good 
prognosis, initially 10  % or less of thyroid carcinomas 
are poorly differentiated or undifferentiated, anaplastic 
subtypes [24, 25]. Loss of differentiation includes loss of 
radioiodine uptake and storage and an aggressive and 
infiltrative growth pattern. Thus, dedifferentiated and 
anaplastic thyroid carcinomas (ATC) are tumours that 
are insensitive to radioiodine treatment, chemothera-
peutic treatment, and external radiation and have a bad 
prognosis [26, 27]. A subgroup of patients with differenti-
ated PTC or FTC also get recurrent disease even under 
TSH suppressive therapy, even though most PTC and 
FTC patients are successfully treated with surgery and 
subsequent radioiodine treatment to destroy residual 
tumour cells [23, 26]. Patients with recurrent disease 
have different outcomes due to the degree of dedifferen-
tiation of their tumour and due to its ability to take up 
radioiodine [26, 28]. Chemotherapeutic treatment of 
dedifferentiated or anaplastic thyroid carcinoma is less 
effective with partial response rates of 25  % or less [29, 
30]. Since most cytotoxic drugs kill cells by inducing cell 
death pathways [14], the resistance of thyroid carcinoma 
cells towards these drugs may point to the cells’ reduced 
ability to undergo cell death. Thus, for dedifferenti-
ated and anaplastic thyroid cancer, facilitating cell death 
induction is one new therapeutic option. Since 7BIO had 
already shown anti-tumour activities in other cell mod-
els, we performed this study to evaluate the effectiveness 
of 7BIO in thyroid carcinoma cells.
Methods
Compounds and antibodies
7BIO came from Enzo Life Sciences (Farmingdale, NY, 
USA), 3-methyladenine (3-MA) and N-(2-Quinolyl)valyl-
aspartyl-(2,6-difluorophenoxy)methyl ketone (Q-VD-
OPh) were provided by Millipore/Calbiochem (MA, 
USA), obatoclax and staurosporine were from Selleck 
Chemicals (Houston, TX, USA). All compounds were 
dissolved in DMSO to 5–10  mM, stored in aliquots at 
−20  °C and further diluted in the appropriate medium. 
Microtubule-associated protein 1A/1B-light chain B 
(LC3B) antibodies were from Cell Signaling Technology 
(Danvers, MA, USA).
Cell lines and cell culture
Cell lines from different subtypes of thyroid cancer were 
used in this study: SW1736 [31], HTh7 [32], C643 [33], 
HTh74 [34], 8305C [35] and 8505C [36] were derived 
from ATC. BHT101 [37], B-CPAP [38] and TPC1 [39] 
were from PTC. ML1 [40], TT2609 [41], FTC133 [42], 
FTC236 [42] and FTC238 [42] were derived from FTCs. 
The FTC133, FTC236 and FTC238 cell lines [42] were 
derived from a single primary FTC, a lymph node metas-
tasis and a lung metastasis from the same patient. Jur-
kat leukemia cells and HepG2 hepatocellular carcinoma 
cells were used as controls. SW1736, HTh7, HTh74 and 
C643 cells were kindly provided by Prof. Heldin (Uppsala, 
Sweden), the other cell lines were purchased from ATCC 
(Manassas, Virginia, USA), ECACC (Salisbury, UK) and 
DSMZ (Braunschweig, Germany).All cells were grown in 
their appropriate medium supplemented with 10 % foe-
tal bovine serum (FBS; Life Technologies, Paisley, PA) at 
37 °C at 5 % CO2.
Cell proliferation studies
For the proliferation assays, 1  ×  104–5  ×  104  cells 
(depending on the cell line) were seeded in each well of 
a 96 well plate. After 24  h, medium was removed and 
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culture medium without FBS containing 0.1  % bovine 
serum albumin (BSA) and the concentrations of 7BIO, 
Q-VD-OPh, 3-MA or a combination of 7BIO and Q-VD-
OPh or 3-MA as indicated or vehicle was added. After 
48 h, viable cells were stained with the Cell Titer Aque-
ous One Solution assay for 2–3  h (Promega, Madison, 
WI, USA) and optical density at 490 nm was read using 
an Emax microplate photometer (Molecular Devices, 
Sunnyvale, CA, USA). Control values without stimula-
tion were performed as 22 fold determinations, while 
all concentrations of 7BIO, Q-VD-OPh and 3-MA were 
tested in eightfold. The results and two-tailed Student’s t 
tests were calculated with SoftMax pro software (Molec-
ular Devices). The IC50 values (drug concentration that 
caused a 50 % reduction in MTT assay) were calculated 
with four parameter logistic function dose–response 
curves using Sigma Plot software (Systat, San Jose, CA, 
USA).
Determination of LDH release and caspase 3/7 activity 
measurement
The CytoTox-ONE homogeneous membrane integrity 
assay (Promega) was used to measure the release of lac-
tate dehydrogenase (LDH) from damaged cells. Activ-
ity of caspases 3 and 7 was measured by the Apo-ONE 
homogeneous Caspase-3/7 assay (Promega). For both 
assays, cells were seeded and grown as described above, 
except that black 96 clear bottom well plates were used. 
On day 2, medium was removed and 100  µl culture 
medium with 0.1  % BSA containing 3  µM 7BIO was 
added to each well. After 24  h, 50  µl of medium from 
each well was transferred to a second 96 well plate and 
equilibrated to 20 °C. 50 µl of CytoTox reagent was added 
and the solution was incubated for 10 min in the dark at 
room temperature. After adding 25  µl of stop solution, 
fluorescence was determined with an excitation wave-
length of 560 nm and an emission wavelength of 590 nm. 
In each experiment, controls without cells and fully lysed 
cells as maximum LDH release controls were included. 
Caspase 3 and 7 activity in 7BIO-treated cells was deter-
mined in the original stimulation plate by adding of 50 µl 
of Apo-ONE reagent that contained a fluorometric cas-
pase substrate, cell lysis reagent and buffer. For positive 
controls, Jurkat cells that grow in suspension culture were 
harvested by centrifugation, resuspended in medium 
with 0.1 % BSA, seeded and staurosporine or a combina-
tion of staurosporine and Q-VD-OPh was added. After 
24 h, 96 well plate was centrifuged, 50 µl of supernatant 
was discarded and Apo-ONE assay was performed. After 
60 min, fluorescence was measured at 521 nm (emission) 
after excitation with 499 nm. All values were determined 
as eightfold determinations. Calculation of results and 
two-tailed Student’s t tests were performed using Soft-
Max pro software (Molecular Devices).
Cell cycle analysis
To perform cell cycle analyses, cells were plated in 6 well 
plates (1 × 105–5 × 105 cells per well) in their appropri-
ate growth medium. After 24  h, medium was removed 
and medium without FBS containing 0.1  % BSA and 
3 µM 7BIO was added for the indicated times. Cells were 
harvested and fixed in ice cold 70  % ethanol. RNase A 
(60 µg/ml) and propidium iodide (25 µg/ml) in PBS were 
added and samples were incubated for 20  min at room 
temperature in the dark. The cellular DNA content was 
measured by means of a FACS Calibur flow cytometer 
(Becton–Dickinson, San Jose, CA) and the cell cycle 
stages and subG1 peak were analysed by ModFit Soft-
ware (Verity Software House, Topsham, ME, USA).
Cell stimulation and protein extraction
For the ELISA and western blot analyses, cells were 
seeded on cell culture dishes (15 cm diameter) and grown 
for 1–2 days until they reached 80–85 % confluence. Full 
medium was replaced with medium containing 0.1  % 
BSA and cells were maintained in this medium for 1  h 
before 3  µM 7BIO or vehicle was added. Non-adherent 
Jurkat cells were harvested by centrifugation, resus-
pended in medium with 0.1  % BSA and staurosporine 
or a combination of staurosporine and Q-VD-OPh was 
added, respectively. After the indicated stimulation times, 
the medium was removed and the cells were washed with 
ice-cold PBS. All additional steps were performed on ice. 
For the cell lysis, a lysis buffer containing protease and 
phosphatase inhibitors (Complete protease inhibitor 
and phosStop phosphatase inhibitor, Roche Applied Sci-
ence, Mannheim, Germany) was used. The lysates were 
clarified by centrifugation at 10,000×g for 10 min at 4 °C. 
The protein concentration was determined with a modi-
fied Bradford assay (Bio-Rad Laboratories, Hercules, CA, 
USA).
Cleaved caspase and cleaved PARP ELISA
A semi-quantitative determination of cleaved caspase 
3 (Asp175) and cleaved poly (ADP ribose) polymerase 
(PARP) as a marker of apoptosis induction and protease 
activation was performed by using specific sandwich 
ELISAs for these cleaved proteins (Cell Signaling Tech-
nologies). In brief, cells were plated, stimulated, and lysed 
as described above. 100 µl of diluted cell lysate contain-
ing 100 µg of total cell protein was incubated in each of 
the antibody coated well of the plate overnight at 4  °C. 
After washing, we used an antibody specific for the 
cleaved protein and a HRP-labelled secondary antibody 
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for detection. The TMB substrate reaction was stopped 
after 30  min at room temperature and the absorbance 
was measured at 450 nm (EMax microplate reader). The 
results were calculated as percent of unstimulated con-
trols using SoftMax pro software (Molecular Devices).
Western blot analyses
Western blot analyses were performed to analyse the 
effects of 7BIO on LC3B cleavage. 30 µg of total protein 
from vehicle stimulated and stimulated cells (see above) 
were denatured by boiling for 5 min in SDS sample buffer. 
Proteins were separated by SDS-PAGE on stain-free poly-
acryl-amide gels (Bio-Rad Laboratories) to enable loading 
control. After electrophoresis, optical densities of stained 
proteins in each lane were documented with a CCD cam-
era system and verified using the Quantity One software 
(both Bio-Rad Laboratories). When the integrated opti-
cal densities of proteins in each lane did not differ more 
than 10  %, proteins were transferred to a nitrocellulose 
membrane (Bio-Rad Laboratories). After blocking with 
BSA, the blots were incubated with the LC3B primary 
antibody (Cell Signaling Technologies) in TBS containing 
0.1  % Triton X100 overnight at 4  °C. After washing, an 
appropriate secondary antibody coupled to horseradish 
peroxidase was added. Detection of bound antigens was 
performed by an enhanced chemiluminescence detec-
tion kit (Amersham ECL Advance, GE Healthcare, Pis-
cataway, NJ, USA). Signal intensity was evaluated with a 
CCD-camera (Bio-Rad Laboratories).
Results
Inhibition of proliferation after 7BIO treatment
14 thyroid cell lines derived from follicular, papillary and 
anaplastic thyroid carcinomas were treated with increas-
ing concentrations of 7BIO or vehicle for 48 h. For all cell 
lines, IC50 values measured by MTT assay are shown in 
Table 1. As examples, results for six cell lines are shown 
in Fig. 1; one data point represents the mean of eight val-
ues ± standard deviation. We found IC50 values for 7BIO 
in a similar range for all cell lines examined independent 
of the subtype of thyroid carcinoma they were derived 
from (1.54–4.83 µM). C643 anaplastic thyroid carcinoma 
cells had the lowest IC50 value (1.54 µM) while BHT101 
cells (dedifferentiated papillary thyroid carcinoma cell 
line) had the highest IC50 value for 7BIO (Table 1) with 
4.83 µM, respectively. These results indicate that 7BIO is 
effective in reducing the number of viable thyroid carci-
noma cells in cell lines derived from various thyroid car-
cinoma subtypes.
Cell cycle analyses after 7BIO treatment
Cell cycle analyses and the following experiments to 
determine the kind of cell death caused by 7BIO were 
performed in the following six cell lines: FTC236 (FTC), 
ML1 (FTC), BHT101 (PTC), SW1736 (ATC), HTh7 
(ATC), and C643 (ATC). Cell cycle analyses of the pro-
pidium iodide stained cellular DNA after a 24  h treat-
ment with 3 µM 7BIO showed a marked increase of cells 
in subG1 fraction in all cell lines analysed, pointing to cell 
death and DNA fragmentation induced by 7BIO treat-
ment (Table 2; Fig. 2). Interestingly, the fraction of cells 
in subG1 fraction was the highest in the two follicular cell 
lines FTC236 and ML1 (43.6 and 44.0  % of cells meas-
ured vs. 9.3–13.1 % in the other cell lines; Table 2). In the 
Table 1 IC50 values of  thyroid carcinoma cell lines 
after 48 h of treatment with 7BIO (MTT assay)
Cell line Origin IC50 7BIO (µM)
FTC133 Follicular 1.98 ± 0.32
FTC236 Follicular 2.21 ± 0.30
FTC238 Follicular 2.17 ± 0.27
ML1 Follicular 4.27 ± 0.38
TT2609 Follicular 4.62 ± 0.51
BHT101 Papillary 4.83 ± 0.36
B‑CPAP Papillary 4.73 ± 0.40
TPC1 Papillary 4.68 ± 0.37
SW1736 Anaplastic 2.52 ± 0.18
HTh7 Anaplastic 3.08 ± 0.25
C643 Anaplastic 1.54 ± 0.21
HTh74 Anaplastic 2.06 ± 0.18
8305C Anaplastic 3.30 ± 0.27






















Fig. 1 Decreased viability of thyroid carcinoma cells after 7BIO 
incubation. Cells were cultured in the presence of increasing 
concentrations of 7BIO or vehicle control for 48 h and viability was 
assessed by MTT assay. Values represent percent of vehicle control, 
mean ± standard deviation from eight‑fold determinations. IC50 
values are shown in Table 1
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remaining living cells, the portion of cells in the G1 phase 
of the cell cycle was significantly increased after incu-
bation with 7BIO in all cell lines except for C643 which 
exhibited a slight, but not significant decrease (Table 2). 
The portion of cells in the G2/M phase and/or the S 
phase of the cell cycle was diminished by 7BIO in all six 
cell lines investigated, although in different ways: while 
ML1 and BHT101 showed a decrease in both G2/M and 
S phases, SW1736 and HTh7 depicted only a decrease 
in S phase. FTC238 had a reduction only in G2/M phase 
and C643 showed an increase of cells in the S phase after 
7BIO treatment, while the portion of cells in G2/M phase 
was significantly diminished (Table 2).
Cell death after 7BIO treatment
Cells treated with 7BIO were analysed biochemically 
to evaluate the kind of cell death induced by this treat-
ment. Figure 3 shows the LDH activity in supernatants of 
vehicle treated cells and cells incubated with 3 µM 7BIO 
for 24  h. All cell lines had a significantly elevated LDH 
content in the stimulation medium after 24 h of stimula-
tion. LDH release in anaplastic SW1736, HTh7 and C643 
cells was significantly higher than in follicular and pap-
illary cell lines following 7BIO treatment. Elevated LDH 
activity in the cell culture medium pointed to a disrup-
tion of cell membranes with a release of LDH and other 
cytoplasmic components and thus reflected thyroid car-
cinoma cell disruption after the 7BIO treatment.
Caspase 3 and 7 measurements as well as the deter-
mination of the cleaved caspase and cleaved PARP were 
performed to investigate apoptotic cell death mecha-
nisms after the 7BIO treatment in thyroid carcinoma 
cells. As shown in Fig.  4, caspase activities were sig-
nificantly elevated after 24  h of 7BIO treatment in all 
thyroid carcinoma cell lines except C643. FTC236, ML1 
and BHT101 cells showed a relatively small, but signifi-
cant increase in caspase activity after 7BIO treatment, 
while SW1736 and HTh7 cells depicted a higher caspase 
activity after incubation with 7BIO. Concentrations of 
cleaved caspase 3 and cleaved PARP as biochemical 
markers of activated caspases were also significantly 
elevated in all treated cells lines except C643 (Figs.  5, 
6) pointing to an activation of the apoptosis machin-
ery in these five cell lines caused by the treatment with 
7BIO. However, the caspase activities depicted by our 
thyroid carcinoma cells were not as high as expected 
since with the concentration of 3  µM 7BIO, approxi-
mately half of the cells were dying (Fig.  1 and con-
trolled by microscopy; data not shown). As positive 
controls for apoptosis induction, Jurkat cells were incu-
bated with 2.5 µM staurosporine. As already described 
in literature [43], this treatment caused apoptosis with 
caspase activation (952 ± 103 % of untreated control), 
as well as an increase in cleaved caspase (1462 ± 98 % 
of untreated control) and cleaved PARP (1271 ± 116 % 
of untreated control). We performed co-incubation of 
thyroid carcinoma cell lines with 7BIO and the gen-
eral caspase inhibitor Q-VD-OPh and measured via-
bility after 48  h. As shown in Table  3, co-incubation 
did not increase the viability of the cells indicating 
that the activation of caspases is not the determining 
step in cell death execution but plays a less important 
role in 7BIO induced cell death of the thyroid car-
cinoma cells examined in this study. As positive con-
trol for Q-VD-OPh treatment, co-incubation of Jurkat 
cells with staurosporine and Q-VD-OPh resulted in a 
decrease of apoptosis induction by staurosporine (cas-
pase activity 135 ±  19 % of untreated control; cleaved 
Table 2 Distribution of cell cycle phases in vehicle-treated and 7BIO-treated cells (24 h, 3 µM)
Values for G1‑, G2/M‑ and S‑phase are determined for the living cells that were not included in the sub‑G1‑peak
* Significant change (p < 0.05, Student’s t test) compared to controls treated with vehicle
Cell line Type Status % subG1 % G1 % G2/M % S
FTC236 Follicular Untreated 0.2 ± 0.1 38.4 ± 4.3 18.7 ± 0.8 42.9 ± 3.0
7BIO 24 h 43.6 ± 4.7* 48.7 ± 4.0* 6.2 ± 0.9* 45.1 ± 5.1
ML1 Follicular Untreated 1.2 ± 0.2 39.4 ± 5.0 29.5 ± 2.4 31.1 ± 3.5
7BIO 24 h 44.0 ± 5.3* 76.8 ± 9.3* 16.9 ± 1.5* 6.3 ± 0.7*
BHT101 Papillary Untreated 0.5 ± 0.2 51.3 ± 4.3 17.4 ± 1.1 31.4 ± 1.5
7BIO 24 h 11.5 ± 2.1* 83.6 ± 6.8* 10.4 ± 0.7* 6.0 ± 1.1*
SW1736 Anaplastic Untreated 1.2 ± 0.2 36.4 ± 3.7 22.1 ± 1.8 41.5 ± 2.4
7BIO 24 h 12.7 ± 1.6* 48.2 ± 6.1* 18.5 ± 3.4 33.3 ± 3.5*
HTh7 Anaplastic Untreated 1.0 ± 0.1 52.0 ± 6.4 15.1 ± 1.3 32.9 ± 2.8
7BIO 24 h 13.1 ± 1.5* 63.3 ± 3.9* 17.3 ± 1.5 19.4 ± 0.9*
C643 Anaplastic Untreated 0.6 ± 0.1 53.8 ± 6.7 12.4 ± 0.7 33.7 ± 1.2
7BIO 24 h 9.3 ± 1.1* 48.7 ± 6.8 5.5 ± 0.3* 45.9 ± 4.5*
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Fig. 2 Cell cycle changes in ML1 and SW1736 cells after incubation with 3 µM 7BIO for 24 h. Cell cycle analysis was conducted using FACS, results 
for ML1 and SW1736 cells are shown as examples. Besides the increase in subG1 peak, in the remaining living cells an increase in G1 phase and a 

















Fig. 3 Increased LDH‑release into the cell culture medium after 
treatment with 3 µM 7BIO for 24 h. Values were determined by 
CytoTox‑assay and are depicted as percent of vehicle‑treated control, 
mean ± standard deviation from eight‑fold determinations; asterisk 

















Fig. 4 Increased activity of caspase 3 and 7 in thyroid carcinoma cell 
lines treated with 3 µM 7BIO for 24 h. Values were determined by the 
ApoOne assay, mean ± standard deviation from eight‑fold determi‑
nations; asterisk indicates significant increase (p < 0.05, Student’s t 
test) compared to controls treated with vehicle
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casapse 144 ± 15 % of untreated control; cleaved PARP 
138 ± 14 % of untreated control).
Finally, LC3B conversion as a marker of autophagic cell 
death was examined by western blot analyses after 7BIO 
treatment. In all six thyroid carcinoma cells examined, 
7BIO treatment did not result in LC3B cleavage which 
indicates that autophagic processes are not involved in 
cell death by 7BIO in thyroid carcinoma cells (Fig.  7). 
HepG2 cells treated with obatoclax, a BH3 mimetic that 
was already reported to cause autophagy and LC3B con-
version [44] were used as positive control for these exper-
iments and depicted a clear conversion of LC3B isoforms 
as expected (Fig. 7). Moreover, co-incubation with 7BIO 
and 3-MA, an autophagy-inhibitor, did not result in an 
increased viability of cells, which again speaks against an 
involvement of autophagic processes in 7BIO induced 
cell death (Table 3).
Discussion
In this study we showed the efficacy of the indirubin 
derivative 7BIO in inducing cell death in thyroid carci-
noma cell lines. The kind of cell death induced was a non-
classical death with cell cycle block, DNA fragmentation 
as well as signs of non-classical apoptosis and necrosis.
The direct pharmacological induction of cell death 
is one possibility to overcome the resistance of cancer 
cells towards apoptosis that is a hallmark of tumour cells 
[12]. Dedifferentiated and anaplastic thyroid carcinoma 
cells that have lost the ability to take up radioiodine are 
tumour cells that are resistant to cell death induction 
by external radiation and chemotherapeutic treatment 
[23]. One reason for this resistance may be the inability 
of these cells to undergo apoptotic cell death [14]. Direct 
induction of cell death therefore presents one possibility 
of new treatment strategies for these tumours. 7BIO is an 
indirubin derivative that has been recently described as 
inducing cell death in some tumour cell lines of various 
origins [3–5]. In this study we showed that 7BIO is also 
active against dedifferentiated thyroid carcinoma cells.
7BIO showed inhibitory effects on all 14 thyroid carci-
noma cell lines investigated. IC50 values of our cell lines 
were in a narrow range (1.54–4.83  µM) with the C643 
ATC cell line being the most sensitive cell line (IC50 
of 1.54  µM; Table  1). All three papillary cell lines had 
IC50 values in the higher range (4.68–4.83 µM; Table 1) 
with BHT101 showing the highest IC50 value of our 
cell lines. In FTC and ATC cell lines, no correlation was 
found between the 7BIO sensitivity and the thyroid carci-
noma subtype from which the cell lines had been derived 
(IC50 values in FTC cell lines 1.98–4.62 µM; IC50 in ATC 
cell lines 1.54–4.32 µM; Table 1). The molecular reasons 
for these differences have to be elucidated and may be 
due to specific activation of signaling pathways in these 
histological thyroid carcinoma subtypes. Moreover, the 
IC50 values in thyroid carcinoma cells were in the lower 
range of that reported in 7BIO-treated cell lines of other 
tumours (2.3–20.0  µM for breast cancer cell lines and 
approx. 12 µM for SH–SY5Y neuroblastoma cells) [3, 5] 
After incubation with 10 µM 7BIO for 48 h, all cell lines 














Fig. 5 Increased concentration of cleaved caspase 3 fragments in 
protein extracts of thyroid carcinoma cells treated with 3 µM 7BIO 
for 24 h. Results of an ELISA specific for caspase 3 fragments are 
depicted, mean ± standard deviation from four‑fold determinations; 
asterisk indicates significant increase (p < 0.05, Student’s t test) com‑
pared to controls treated with vehicle
Fig. 6 Increased concentration of cleaved PARP fragments in 
protein extracts of thyroid carcinoma cells treated with 3 µM 7BIO 
for 24 h. Results of an ELISA specific for PARP fragments are depicted, 
mean ± standard deviations from four‑fold determinations; asterisk 
indicates significant increase (p < 0.05, Student’s t test) compared to 
controls treated with vehicle
Page 8 of 11Broecker‑Preuss et al. Cancer Cell Int  (2015) 15:97 
pointing to cell death in the majority of cells. A simi-
lar effect was already described by Ribas et  al. [4] who 
showed that a 24 h treatment with 25 µM 7BIO was lethal 
for the entire cell population of SH-SY5Y neuroblastoma 
cells and Jurkat leukaemia cells. Our biochemical data 
in six 7BIO-treated thyroid carcinoma cells argue for 
an atypical kind of cell death with biochemical signs 
of necrosis, DNA fragmentation, cell cycle inhibition, 
and atypical apoptosis. An increased LDH release typi-
cal for cell death by necrosis or secondary necrosis was 
seen in all six cell lines examined after 7BIO stimulation. 
In parallel, a small but significant increase in activity of 
caspases seen as direct caspase activity and increase in 
caspase cleavage products was found in all cells but C643. 
However, the significance of apoptosis-induction for 
cell death in 7BIO stimulated cells has to be questioned 
since the pan-caspase inhibitor Q-VD-OPh did not sig-
nificantly prevent cell death by 7BIO (Table  3). Similar 
results have already been described in other cell lines for 
7BIO. In neuroblastoma cells and the T cell leukemia cell 
line Jurkat, cell death by an apoptosis-independent man-
ner was induced by 7BIO [3, 4]. In IMR-5, IMR-32, Jur-
kat and HL-60 cells, 7BIO treatment killed cells without 
activating caspases [3, 45]. Nicolaou et al. [5] on the other 
hand reported on 7BIO-mediated apoptosis induction 
by caspase-dependent as well as by caspase-independent 
pathways in breast cancer cell lines with an increase in 
the uncleaved caspases 3 and 9. From their own data and 
data in the literature these authors concluded that the 
response of different tumour cell lines to 7BIO through 
apoptotic or non-apoptotic mechanisms is a function of 
cell content [5]. Our own data suggest a cell death mech-
anism in which caspase activation occurs but is of little 
importance. This thesis is supported by the C643 anaplas-
tic thyroid carcinoma cell line that was the most sensitive 
cell line towards 7BIO incubation but showed no signifi-
cant activation of caspases by 7BIO. Caspase-independ-
ent cell death by apoptosis has already been described 
in various cell systems [46]. Physiologically it occurs in 
cells expressing endogenous caspase inhibitors like XIAP, 
CrmA or AIF [47–50]. In affected cells, apoptosis-like 
death is generally caused by serine-protease-mediated 
Table 3 Viability of  cells after  incubation with  3  µM 7BIO, 5  µM Q-VD-OPh, 2  µM 3-MA or the combinations indicated 
for 24 h (MTT assay)
* Significant decrease (p < 0.05, Student’s t test) of 7BIO‑treated cells compared to vehicle‑treated controls, while treatment with Q‑VD‑OPh or 3‑MA alone had 
no significant effect compared to vehicle‑treated controls. Treatment with a combination of 7BIO and Q‑VD‑OPh or 7BIO and 3‑MA was compared with the 7BIO 
treatment and had no significant effects
Cell line Origin 7BIO Q-VD-OPh 7BIO + Q-VD-OPh 3-MA 7BIO + 3-MA
FTC236 Follicular 41.5 ± 4.8* 102.4 ± 6.9 45.2 ± 7.2 94.6 ± 10.4 39.3 ± 7.8
ML1 Follicular 72.3 ± 4.2* 105.1 ± 6.0 70.3 ± 6.8 106.0 ± 7.5 71.6 ± 7.7
BHT101 Papillary 68.3 ± 8.3* 97.4 ± 8.2 71.2 ± 5.3 98.4 ± 5.7 69.4 ± 9.4
SW1736 Anaplastic 39.5 ± 8.2* 95.7 ± 11.4 44.5 ± 9.1 104.6 ± 9.7 42.6 ± 9.5
HTh7 Anaplastic 50.8 ± 6.2* 100.6 ± 7.9 53.5 ± 8.3 106.7 ± 10.3 49.2 ± 7.5






























Fig. 7 Absence of conversion of LC3B‑I after treatment with 3 µM 
7BIO indicating no involvement of autophagic processes in 7BIO‑
mediated cell death. Western blot analyses of vehicle‑treated and 
7BIO‑treated thyroid carcinoma cell lines using LC3B antibody. As a 
positive control for autophagy induction, HepG2 cells treated with 
0.2 µM obatoclax were included. Equal protein loading was ensured 
by in‑gel protein staining (see “Methods”)
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processes [51] that mediate the cleavage of cellular sub-
strates similar to caspase-induction. The lysosomal pro-
teases cathepsin D and B as well as calpains and other 
serine-proteases and are involved in this caspase-inde-
pendent, apoptosis-like cell death [52–55]. The findings 
on the kind of cell death in our 7BIO-stimulated thyroid 
carcinoma cell lines are in accordance with these findings 
in cell lines undergoing cell death after various stimuli 
and also with the recently reported results of Ribas et al. 
[4] who reported on the involvement of serine proteases 
in 7BIO-induced cell death. Further experiments to ana-
lyse protease activation and to characterize intracellular 
targets of 7BIO may elucidate the exact kind of cell death 
induced by 7BIO.
Regarding increases in subG1 fraction after 7BIO treat-
ment, follicular FTC236 and ML1 cells interestingly 
showed a large fraction of cell in subG1 peak pointing 
to massive DNA fragmentation in these cells like already 
described by others [5]. In the other cell lines examined, 
fractions of cells in subG1 fraction were also significantly 
elevated, but to a lesser extent. Since DNA fragmenta-
tion can be mediated by various proteolytic enzymes, a 
caspase-independent mechanism of DNA fragmentation 
probably occurred with different degrees of activation in 
different 7BIO-treated thyroid carcinoma cell lines. In 
other cell lines, a caspase-independent, serine protease 
mediated DNA cleavage has already been described [51, 
56, 57]. However, DNA fragmentation resulting in an ele-
vated subG1 fraction may also occur during necrotic cell 
death [58] and in our cells may reflect a mixed kind of cell 
death with non-classical apoptosis and necrotic features. 
This interpretation is in accordance with data from the 
literature that cell death in vivo is often characterized not 
by a single cell death mode but can comprise elements 
of apoptotic, necrotic, and sometimes autophagic ele-
ments. Accordingly, various kinds of cell death can occur 
independently of each other or simultaneously resulting 
in a combined cell death phenotype [59, 60]. Cell cycle 
analyses of the remaining living cells pointed to different 
regulation mechanisms in various thyroid carcinoma cell 
lines treated with 7BIO. All cell lines except C643 showed 
a significant increase in the portion of cell in G1 fraction 
after incubation with 7BIO. This is in contrast to some 
other cell lines described in the literature that exhibited 
a decrease in G1 fraction following 7BIO treatment [3, 
5] that is also described for other indirubins [6, 61, 62]. 
C643 cells showed a similar cell cycle distribution with a 
small, but not significant decrease in G1 phase (Table 2). 
The activation of different checkpoints of the cell cycle 
points to different cellular backgrounds of cells with 
respect to cell cycle regulatory proteins like p53, pRb as 
well as CDKs and its regulatory proteins [63]. Further 
studies may reveal the correlation of expression pattern 
of cell cycle regulatory proteins with the cellular effects of 
7BIO treatment in different cells.
Conclusion
In summary, we found that 7BIO efficiently killed dedif-
ferentiated and anaplastic thyroid carcinoma although 
its exact mechanism of action and the exact kind of cell 
death induced by 7BIO is not yet known and needs fur-
ther investigation. Nevertheless, 7BIO and related indiru-
bin components like 6BIO and other recently described 
indirubin derivatives [7–11] may have value as a new 
therapeutic option for dedifferentiated thyroid cancer.
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